论文部分内容阅读
目的:确定他克莫司与罗格列酮单独及联合应用对肿瘤坏死因子-α(TNF-α)诱导的HaCaT细胞LI37及核因子-κB(NF-κB)表达的影响。方法:利用TNF-α诱导体外培养的HaCaT细胞处于炎性状态,在不同浓度的他克莫司与罗格列酮单独及联合作用下,采用RT-PCR法检测LI37的表达情况,采用免疫细胞化学(SABC)法检测NF-κB的表达情况。结果:(1)TNF-α诱导的HaCaT细胞中LI37及NF-κB的表达显著高于对照组(P<0.05)。(2)他克莫司、罗格列酮单独及联合应用均可显著抑制TNF-α诱导的HaCaT细胞LL37及NF-κB的表达(P<0.05);二者联合应用的作用效果均较单独用药组更强(P<0.05)。结论:他克莫司和罗格列酮联合应用能增强其对TNF-α诱导的LL37及NF-κB表达的抑制作用。
OBJECTIVE: To determine the effects of tacrolimus and rosiglitazone, alone and in combination, on the expression of LI37 and NF-κB in HaCaT cells induced by tumor necrosis factor-α (TNF-α). Methods: HaCaT cells induced by TNF-α were in an inflammatory state. The expression of LI37 was detected by RT-PCR at different concentrations of tacrolimus and rosiglitazone alone or in combination. Immunofluorescence The chemical (SABC) method was used to detect the expression of NF-κB. Results: (1) The expression of LI37 and NF-κB in HaCaT cells induced by TNF-α were significantly higher than those in control group (P <0.05). (2) Both tacrolimus and rosiglitazone could significantly inhibit the expression of LL37 and NF-κB in HaCaT cells induced by TNF-α (P <0.05), both alone and in combination. The medication group was stronger (P <0.05). Conclusion: The combination of tacrolimus and rosiglitazone can enhance the inhibitory effect of TNF-α on the expression of LL37 and NF-κB.